Others

Haihe Biopharma's Liporaxel Wins NMPA Approval for HER2‑Negative Breast Cancer – World's First Oral Paclitaxel Expands into Second Indication in China
3SBioHaihe Biopharma

Haihe Biopharma’s Liporaxel Wins NMPA Approval for HER2‑Negative Breast Cancer – World’s First Oral Paclitaxel Expands into Second Indication in China

Shanghai Haihe Biopharma Co., Ltd, a partner of 3SBio Inc. (HKG: 1530), announced that its paclitaxel oral solution (registered trademark: Liporaxel; development code: RMX3001/DHP107), developed in collaboration with South Korea‑based…

Humanwell Healthcare Subsidiary Wins FDA ANDA Approval for Diltiazem Hydrochloride Tablets – Expanding U.S. Generic Cardiovascular Portfolio

Humanwell Healthcare Subsidiary Wins FDA ANDA Approval for Diltiazem Hydrochloride Tablets – Expanding U.S. Generic Cardiovascular Portfolio

AbbVie Secures Dual FDA Breakthrough Therapy Designations for Temab‑A in Colorectal and Lung Cancers – Next‑Gen c‑Met ADC Advances

AbbVie Secures Dual FDA Breakthrough Therapy Designations for Temab‑A in Colorectal and Lung Cancers – Next‑Gen c‑Met ADC Advances

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
CSPC PharmaceuticalHKG: 1093

CSPC Pharmaceutical Receives NMPA Approval for First-in-Class mRNA-LNP Dual-Target CAR-T Therapy SYS 6063 in Systemic Lupus Erythematosus

HKG: 6938Ribo Life Science

Suzhou Ribo Life Science Files Phase II EMA Application for RBD1119 – Novel siRNA Antithrombotic for Coronary Artery Disease

Hotgen BiotechSHA: 688068

Hotgen Biotech Secures NMPA Clinical Filing Acceptance for SGC001 Monoclonal Antibody in Severe Acute Pancreatitis

CanSino Biologics Initiates Phase I/II Trial for PCV24 Pneumococcal Conjugate Vaccine with Enhanced Serotype Coverage

Show More